We have studied the efficacy of granisetron, a selective 5-hydroxytryptamine type 3 receptor antagonist, administered orally for the prevention of postoperative vomiting after tonsillectomy in children. In a randomized, double-blind, placebo-controlled study, 160 paediatric patients, ASA I, aged 4-10 yr, received placebo or granisetron (20, 40 or 80 g kg 91 ) (n:40 each) orally, 1 h before surgery. A standard general anaesthetic technique was used throughout A complete response, defined as no emesis and no need for another rescue antiemetic during the first 24 h after anaesthesia, occurred in 40%, 48%, 85% and 90% of patients who had received placebo, or granisetron 20, 40 or 80 g kg 91 , respectively (P:0.05; overall Fisher's exact probability test). There were no clinically important adverse events. We conclude that preoperative oral granisetron, in doses more than 40 g kg 91 , was effective for the prevention of postoperative vomiting in children. (Br.
The incidence of vomiting after tonsillectomy in children is high when no prophylactic antiemetic is provided. 1 A variety of pharmacological approaches (antihistamines, butyrophenones, dopamine receptor antagonists) have been investigated in the prevention and treatment of postoperative emesis, but undesirable adverse effects, such as excessive sedation, hypotension, dry mouth, dysphoria, hallucinations and extrapyramidal symptoms have been noted. 2 Ondansetron, a selective 5-hydroxytryptamine type 3 (5-HT 3 ) receptor antagonist, is a prophylactic antiemetic for the prevention of vomiting after tonsillectomy in children. 3 4 Granisetron, another new 5-HT 3 receptor antagonist, has more potent and longer acting properties than Ondansetron, 5 and reduced the incidence of postoperative emesis in paediatric patients undergoing tonsillectomy with or without adenoidectomy. 6 However, granisetron is more expensive than other antiemetics, such as droperidol and metoclopramide, commonly used for the prevention of postoperative emesis. Oral granisetron is less expensive than the i.v. formulation and is effective against cisplatin-induced emesis. 7 We conducted a randomized, double-blinded, placebocontrolled study to determine the efficacy of oral granisetron in the prevention of postoperative vomiting in children undergoing tonsillectomy.
Patients and methods
After obtaining approval from the Institutional Review Board and informed parental consent, we studied 160 ASA I children, aged 4-10 yr, undergoing elective tonsillectomy with or without adenoidectomy. Children who had experienced postoperative vomiting, who had received antiemetic medication within 24 h before surgery, and who had a history of motion sickness were excluded.
Patients were allocated randomly to one of four groups (n:40 in each) using computer-generated random numbers concealed in envelopes, to receive orally either placebo or granisetron at three different doses (20, 40 or 80 g kg
91
), 1 h before surgery. Syrups with and without granisetron were prepared for each study group by a pharmacist.
Solid food was not allowed after midnight and clear liquids were permitted up to 3 h before surgery. As premedication, all patients were given bromazepam 3 mg rectally, 1 h before operation. Anaesthesia was induced with sevoflurane and nitrous oxide in oxygen via a mask. Tracheal intubation was facilitated with vecuronium 0.1 mg kg 91 i.v. After tracheal intubation, anaesthesia was maintained with 0.5-3.0% sevoflurane (inspired concentration) and 66% nitrous oxide in oxygen. Ventilation was controlled mechanically and adjusted to maintain an end-tidal carbon dioxide partial pressure of 4.2-5.3 kPa using an anaestheticrespiratory gas analyser (Ultima, Datex, Helsinki, Finland). Neuromuscular block was achieved with vecuronium and antagonized by a combination of atropine 0.02 mg kg 91 and neostigmine 0.04 mg kg 91 i.v. at the end of surgery. Before tracheal extubation, the nasal or orogastric tube was inserted and suction applied to empty the stomach of air or other contents, and then the tube was removed. The trachea was extubated when the patient was awake. Rectal temperature was monitored and maintained at 37<1 ЊC throughout surgery. After operation, all patients were admitted to the hospital and remained for 2 days. Clear liquids were offered only if the patient requested, and other oral fluids were was not allowed for 4 h after recovery from anaesthesia. If two or more episodes of vomiting occurred during the first 24 h after anaesthesia, another rescue antiemetic (e.g. domperidone rectally) was given. Postoperative analgesia was provided with paracetamol 10-25 mg kg 91 rectally for mild to moderate pain and pentazocine 0.3 mg kg 91 i.v. for severe pain. After operation, all episodes of retching and vomiting during the first 24 h after anaesthesia were recorded by nursing staff blinded to the treatment each patient had received. Nausea was not assessed in this study because of the age of the patients. A complete response was defined as no retching, no vomiting and no need for another rescue antiemetic during the first 24 h after anaesthesia. Details of adverse events were recorded by nurses who interviewed the parents of each patient.
Patient data were analysed using one-way analysis of variance (ANOVA), Student's t test and chi-square test, where appropriate. The incidence of complete response, retching and vomiting, rescue antiemetic required and adverse events were compared using Fisher's exact probability test. P:0.05 was considered significant. All values are expressed as mean (SD) and number (%). Forty patients in each group were sufficient to detect a difference with a:0.05 and power 19ß:0.8.
Results
Patient characteristics and anaesthesia data are summarized in table 1. There were no significant differences between groups.
There was a complete response in 16 of 40 (40%) patients who had received placebo, in 19 of 40 (48%) of those who had received granisetron 20 g kg The most frequently reported adverse events were headache, drowsiness and constipation. There were no differences between the four groups in the number of patients who complained of these symptoms (table 3) .
Discussion
We have demonstrated recently that i.v. granisetron reduced the incidence of postoperative emesis in children undergoing tonsillectomy with or without adenoidectomy. 6 However, the fact that granisetron is more expensive than other antiemetics may delay its widespread use. Oral granisetron is less expensive than the i.v. form. 7 Preoperative oral granisetron 40 g kg 91 and 80 g kg 91 provided more effective antiemetic prophylaxis than placebo, but there was no difference in complete response between the placebo and granisetron 20 g kg 91 groups. The cause of a high incidence of emesis after paediatric tonsillectomy remains unclear, but is probably multifactorial. 2 A number of factors, including age, obesity, history of motion sickness or previous postoperative emesis, operative procedure, anaesthetic technique and postoperative pain are considered to increase the incidence of postoperative vomiting. However, in this study there were no differences between the groups with regard to patient data, surgical procedure, anaesthetics administered and analgesics used after operation, and children with a history of motion sickness or previous emesis were British Journal of Anaesthesia excluded. Therefore, the difference in the incidence of complete response between the groups can be attributed to differences in the antiemetics tested. I.v. granisetron has been shown previously to be effective against emesis induced by cancer chemotherapy 8 and recently in children undergoing tonsillectomy with or without adenoidectomy. 6 Oral granisetron has been shown to be effective in the treatment of chemotherapy-induced emesis. 9 Our study demonstrated that the incidence of complete response in patients who had received oral granisetron 40 and 80 g kg 91 was higher than in those who had received placebo. The exact mechanism of action of granisetron in preventing postoperative emesis remains unclear but it has been suggested that it may act on sites containing 5-HT 3 receptors with demonstrated antiemetic effects. 10 We could find no report on the minimum effective dose of oral granisetron for the prevention of postoperative emesis in children. However, our study demonstrated that the antiemetic efficacy of granisetron 40 g kg 91 was similar to that of granisetron 80 g kg
91
, and also that there were no differences in complete response between placebo and granisetron 20 g kg
. This suggests that granisetron 40 g kg 91 may be an effective antiemetic for the prevention of vomiting after paediatric tonsillectomy, and that increasing the dose to 80 g kg 91 provides no demonstrable benefit. This study also showed that nine of 40 patients who had received placebo and eight of those who had received granisetron 20 g kg 91 required another rescue antiemetic (e.g. domperidone) for the treatment of severe vomiting (i.e. two or more episodes of vomiting), compared with none who had received granisetron 40 or 80 g kg 91 (P:0.001). The most commonly reported adverse events were headache, drowsiness and constipation. The incidence of these symptoms was comparable between groups. Therefore, oral granisetron may be considered to be relatively free of adverse effects for preventing postoperative emesis in children.
The results of this study are important because of the potential reduction of cost of therapy. In Japan, our hospital pharmacy pays $12.6 for oral granisetron 1 mg (approximately 40 g kg
) and $33.4 for granisetron 1 mg i.v. The cost of granisetron is higher than that of other antiemetics, such as droperidol and metoclopramide. However, the use of these antiemetics has been limited because of their undesirable adverse effects, such as excessive sedation and extrapyramidal symptoms. 2 In summary, we have found that preoperative oral granisetron, in doses greater than 40 g kg
, was effective for the prevention of postoperative vomiting in children undergoing tonsillectomy. R e t r a c t e d
